Moreover, Hennes et al. suggested that a cutoff higher than previously anticipated (e.g., ≥1,280) can be used to increase the specificity for a non-MS disease course and facilitate the interpretation of MOG assay results [9]. This evidence concerns the gene MOG and myeloid sarcoma.